[go: up one dir, main page]

SG11201900459RA - Mg53 mutants, methods of making the same, and uses thereof - Google Patents

Mg53 mutants, methods of making the same, and uses thereof

Info

Publication number
SG11201900459RA
SG11201900459RA SG11201900459RA SG11201900459RA SG11201900459RA SG 11201900459R A SG11201900459R A SG 11201900459RA SG 11201900459R A SG11201900459R A SG 11201900459RA SG 11201900459R A SG11201900459R A SG 11201900459RA SG 11201900459R A SG11201900459R A SG 11201900459RA
Authority
SG
Singapore
Prior art keywords
mutants
making
methods
same
Prior art date
Application number
SG11201900459RA
Inventor
Rui-Ping Xiao
Fengxiang Lu
Yan Zhang
Sile Guo
Original Assignee
Univ Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610847346.4A external-priority patent/CN107868125A/en
Application filed by Univ Beijing filed Critical Univ Beijing
Publication of SG11201900459RA publication Critical patent/SG11201900459RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201900459RA 2016-08-01 2017-07-20 Mg53 mutants, methods of making the same, and uses thereof SG11201900459RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610621989 2016-08-01
CN201610847346.4A CN107868125A (en) 2016-09-23 2016-09-23 MG53 mutant and its production and use
CN201710560975 2017-07-11
PCT/CN2017/093640 WO2018024110A1 (en) 2016-08-01 2017-07-20 Mg53 mutant, and preparation method therefor and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900459RA true SG11201900459RA (en) 2019-02-27

Family

ID=61073266

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900459RA SG11201900459RA (en) 2016-08-01 2017-07-20 Mg53 mutants, methods of making the same, and uses thereof

Country Status (10)

Country Link
US (1) US11306296B2 (en)
EP (1) EP3492491A4 (en)
JP (1) JP7144402B2 (en)
KR (1) KR102483242B1 (en)
CN (1) CN108473546B (en)
CA (1) CA3031856C (en)
MA (1) MA45797A (en)
SG (1) SG11201900459RA (en)
TW (1) TWI781948B (en)
WO (1) WO2018024110A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108478800A (en) * 2018-04-02 2018-09-04 慎东 The composition of its mutant containing MG53/ is in the application for preparing inflammatory bowel medicine
US20200179482A1 (en) * 2018-12-07 2020-06-11 Ohio State Innovation Foundation Composition for and method of facilitating corneal tissue repair
EP3982999A4 (en) * 2019-06-17 2023-07-19 Trim-Edicine, Inc. Composition for and method of treating hepatic tissue injury
CN115379823A (en) * 2020-01-23 2022-11-22 俄亥俄州立创新基金会 Cosmeceutical composition
CN119452081A (en) * 2022-06-28 2025-02-14 神济昌华(北京)生物科技有限公司 AAV gene therapy for treating neurological diseases
US20250382342A1 (en) * 2022-06-28 2025-12-18 Sineugene Therapeutics Co., Ltd. A truncated protein and use thereof
WO2024002059A1 (en) * 2022-06-28 2024-01-04 Sineugene Therapeutics Co., Ltd. Method for treating a parkinson's disease
WO2024249316A1 (en) * 2023-05-26 2024-12-05 Ohio State Innovation Foundation Recombinant trim72/mg53 polypeptides and methods of use thereof
WO2024249315A1 (en) * 2023-05-26 2024-12-05 Ohio State Innovation Foundation Modified mg53 polypeptides and methods of use thereof
WO2025030108A2 (en) * 2023-08-03 2025-02-06 Ohio State Innovation Foundation Recombinant human mitsugumin-53 compositions and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
ES2329904T3 (en) 2003-10-07 2009-12-02 United Therapeutics Corporation MUTANT OF TYROSINASE AND PROCEDURES FOR USING THE SAME.
JP5248494B2 (en) 2006-07-11 2013-07-31 ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー Protein, nucleic acid encoding it and related methods of use
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
KR101413005B1 (en) 2007-12-04 2014-07-02 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Compositions and methods to modulate cell membrane resealing
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
CN101797375B (en) * 2009-12-02 2013-01-23 北京大学 Application of MG53 protein for preventing and/or treating myocardial ischemia/reperfusion injury
CN101912617B (en) * 2010-07-29 2012-09-26 北京大学 Application of MG53 gene to treatment of insulin resistance, type II diabetes mellitus and related diseases thereof
CN103430023B (en) 2010-11-05 2016-05-04 罗格斯新泽西州立大学 Serum MG53 as a diagnostic marker for tissue damage
US20140024594A1 (en) * 2011-03-31 2014-01-23 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
WO2012134478A1 (en) * 2011-03-31 2012-10-04 University Of Medicine And Dentistry Of New Jersey Compositions and methods for the treatment and prevention of cardiac ischemic injury
EP2753363A4 (en) * 2011-09-07 2015-03-11 Univ New Jersey Med COMPOSITIONS COMPRISING MG53 AND METHODS FOR TREATING AND PREVENTING INJURIES AT THE RESPIRATORY LEVEL
CN103965342B (en) * 2013-01-25 2015-06-10 北京博雅和瑞科技有限公司 MG53 mutant, and mutation method and application thereof
CN103966227B (en) 2014-03-06 2015-05-27 北京博雅和瑞科技有限公司 Coding nucleotide sequence of MG53 (mitsugumin53) protein with codon optimization, recombinant of MG 53 protein as well as application of MG 53 protein
CN107266551B (en) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 MG53 mutant and preparation method and application thereof
CN107987147B (en) * 2016-10-26 2024-07-05 牡丹江友搏药业有限责任公司 MG53 polymer preparation method and application thereof
CN108721601A (en) 2018-07-26 2018-11-02 海南博芝康医疗科技有限公司 A kind of composition prevented and/or treat injury of kidney and kidney failure
CN109432404A (en) 2018-12-26 2019-03-08 牡丹江友搏药业有限责任公司 One kind albumen containing MG53/MG53 mutant protein gel and its preparation method and application
CN109528684A (en) 2018-12-26 2019-03-29 牡丹江友搏药业有限责任公司 A kind of MG53 albumen/MG53 mutant protein capsulae enterosolubilis and preparation method thereof

Also Published As

Publication number Publication date
CN108473546A (en) 2018-08-31
CN108473546B (en) 2022-08-16
KR102483242B1 (en) 2022-12-29
CA3031856C (en) 2024-06-25
US20190153406A1 (en) 2019-05-23
US11306296B2 (en) 2022-04-19
JP2019530433A (en) 2019-10-24
JP7144402B2 (en) 2022-09-29
EP3492491A4 (en) 2020-02-19
CA3031856A1 (en) 2018-02-08
MA45797A (en) 2021-04-21
TW201805299A (en) 2018-02-16
HK1255559A1 (en) 2019-08-23
WO2018024110A1 (en) 2018-02-08
TWI781948B (en) 2022-11-01
EP3492491A1 (en) 2019-06-05
KR20190034278A (en) 2019-04-01
WO2018024110A8 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
IL276515B2 (en) Pd-l1-specific antibodies and methods of using the same
EP3601528A4 (en) Cells and methods of uses and making the same
ZA202008011B (en) Polyether derivatives, uses, and methods of making the same
IL254734A0 (en) Modified t cells and methods of making and using the same
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
SG11201900459RA (en) Mg53 mutants, methods of making the same, and uses thereof
IL268354A (en) Microbial cells, methods of producing the same, and uses thereof
EP3209137A4 (en) Metastable, translucent flavor nanoemulsions and methods of preparing the same
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
GB201519128D0 (en) Solid forms and methods of preparing the same
ZA201806640B (en) Gitr antibodies, methods, and uses
EP3200596A4 (en) Stabilized oil and methods of making the same
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
GB201603311D0 (en) New uses and methods
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
IL262747A (en) Anti-kv1.3 antibodies, and methods of production and use thereof
SG11201803485UA (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
GB201612858D0 (en) New uses and methods
SG11202001195PA (en) Gyroscope, methods of forming and operating the same
EP3233124A4 (en) Nanowire-coated microdevice and method of making and using the same
GB2548839B (en) New uses and methods
EP3334730A4 (en) Pyrrolomycins and methods of using the same
EP3294763A4 (en) Glucanase production and methods of using the same
PL3234386T3 (en) Sliding component and method of forming the same
PL3668907T3 (en) Epoxidized polyfarnesene and methods for producing the same